Life sciences start-up support powered by NGI

Starting up a company is tricky in any sector. It is particularly tough in one that is as fast moving as life sciences. The Netherlands Genomics Initiative fully recognises this difficulty and has put together a coherent support programme for life sciences starters by initiating a series of activities and partnering with existing start-up programmes.

Out now: Nice to meet you too
Following the success of ‘Nice to meet you’, published by LifeSciences@work in June 2011, we are happy to present a new and expanded overview of start-ups in Dutch life sciences entitled ‘Nice to meet you too’.

Download the publication in our library!

Find out how we can help you!

LifeSciences@work brings start-up support activities, former- and future participants and experts community together. The support programme covers aspects such as coaching/training, financial support and networking activities.

  • I have an idea for a new business.

    What should I do next?

    Get coaching!

    Read more »

  • I need to improve my business skills.

    What are my options?

    Get training!

    Read more »

  • I have a (draft) business plan.

    How do I get my business started?

    Get financing!

    Read more »

  • I have just started a company.

    Where can I get answers to day-to-day issues?

    Get connected!

    Read more »

Latest News

  • 26 January 2012 Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced that it has raised €23 million in new equity financing. Read more »
  • 18 January 2012 Waste2Chemical BV and Wageningen UR: Mibiton Science financing pilot facility to valorise organic waste to biochemicals. In December 2011, the Board approved investment in the first Mibiton Science facility, which was submitted by the start-up company Waste2Chemical BV and Wageningen University. Read more »
  • 19 December 2011 to-BBB, the Dutch brain drug delivery company, has been awarded a grant of over €600,000 through the “Internationaal Innoveren” program of the Dutch government agency Agentschap NL to support a brain drug delivery partnership with a top-5 pharma company. Read more »
  • 14 December 2011 The Fall 2011 edition of the Venture Challenge took a surprising turn when two winners were announced during the Dutch Life Sciences & Health conference in Media Plaza, Utrecht. Life sciences ventures Muscabiotics and Prognostix will split the €25,000 prize money. Read more »
  • 01 December 2011 Thuja Capital's portfolio company ArGEN-X, a biopharmaceutical company focussed on the development of human monoclonal antibodies from its propeitory SIMPLE antibody platform, announced the successfully closing of a EUR 27.5 million (USD 37 million), serie B financing round. Read more »
View all »

Open Calls & Deadlines

  • Venture Challenge Spring 2012
    The Call for the Venture Challenge Spring 2012 has been opened! Submit your proposal by 6 March 2012, 12:00 hrs at the latest. Read more »
View all »